Short answer
Cencora (COR) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $84.8B (up 5.1% year over year) with net income of $764M.
Q2 2026 key financials · XBRL
- Revenue
- $84.8B
- +5.1% YoY · +8.2% QoQ
- Net income
- $764M
- +11.1% YoY · −53.5% QoQ
- Operating margin
- 1.3%
- Gross margin
- 4.3%
- EPS (diluted)
- $3.94
- +11.9% YoY · −53.1% QoQ
Source: XBRL data from the Cencora (COR) Q2 2026 10-Q on SEC EDGAR. USD.
Cencora Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $84.8B, up 5.1% YoY from $80.7B, driven by U.S. Healthcare Solutions growth
- U.S. Healthcare Solutions strongest segment: revenue $74.9B, up 4.9%; GLP-1 sales $2.3B, up 25.5%
- Gross margin 4.26% vs 3.60% YoY; operating margin 1.32% vs 1.08% YoY
- Operating cash flow $1.7B versus $0.7B YoY; $3.0B senior notes and $1.5B term loans issued for OneOncology
- Outlook: GLP-1 demand supports growth; headwinds include generic conversions, pricing pressure, reimbursement pressure, and customer consolidation
Risk Factors
- No risk-factors section provided; excerpt covers issuer share repurchases only
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Cencora quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.